Semax Dosage and Nasal Protocol: A Clinical Guide for Standard, NA-Semax, and the Amidate Form

The single most common question after a patient decides to trial Semax is not about its mechanism or its clinical history — it is about the bottle in their hand. How many drops? Which nostril first? Is the NA-Semax dose the same? What changes if they are cycling it for neuroprotection versus acute cognitive load?

This article answers those questions with the precision they deserve. I have covered the mechanistic background and evidence base for Semax extensively elsewhere; here the focus is entirely on administration — variant-by-variant dosing, titration sequences, cycling frameworks, and the practical technique details that determine whether a patient actually absorbs the peptide they paid for.

At a Glance

Why Dosing Differs by Variant

Before addressing dose numbers, it is worth understanding why Semax variants are not interchangeable in their dosing.

Standard Semax (heptapeptide: Met-Glu-His-Phe-Pro-Gly-Pro) is the molecule with the longest clinical history — approved in Russia since 1991 and studied at the 0.1% concentration (1 mg/mL) across most published trials. The Russian pharmaceutical formulation delivers approximately 100 mcg per three drops.

NA-Semax (N-acetylated Semax) has an acetyl group added to the N-terminus, which significantly increases resistance to enzymatic degradation in nasal mucosa and plasma. In practical terms, this means a higher fraction of the dose reaches olfactory nerve fibers intact. Users and clinicians who have worked with both forms consistently report that NA-Semax produces more pronounced effects at equivalent microgram doses — meaning the effective dose is lower, not that the molecule is inherently more potent in receptor binding.

NA-Semax Amidate adds C-terminal amidation to the already-acetylated backbone, further extending metabolic half-life. It represents the most structurally stable variant and, in the preclinical literature, shows the highest BDNF upregulation per dose unit. Clinical experience suggests starting doses roughly 30–50% lower than NA-Semax until individual tolerance is established.

The practical consequence: a patient who transitions from standard Semax 0.1% to NA-Semax Amidate at the same microgram dose will very likely feel over-stimulated. I always advise starting the modified forms at half the mcg equivalent and titrating up over 5–7 days.

Standard Semax 0.1%: Dosing Protocol

Starting Titration

For patients new to Semax or new to intranasal peptides generally, I recommend beginning at the lower end of the dose range regardless of what they may have read about typical clinical doses.

Week 1 (Orientation phase):

• 1–2 drops per nostril once daily = approximately 70–130 mcg total
• Administer in the morning, 30–60 minutes before cognitive demands begin
• Monitor for stimulant-like effects: increased mental drive, mild restlessness, or headache at the back of the skull (common at higher doses in sensitive individuals)

Week 2–3 (Titration phase):

• If week 1 is well tolerated with desired cognitive effects: remain at this dose
• If effects are subtle: increase to 3 drops per nostril once daily (~200 mcg total) or add a second administration in the early afternoon
• Upper practical limit for most patients: 3 drops per nostril twice daily = ~400–600 mcg/day

Upper bound: Russian clinical trials studied doses up to 900 mcg/day in divided doses for acute neurological indications (stroke, TBI). For outpatient cognitive enhancement, I rarely advise exceeding 600 mcg/day. Higher doses do not appear to substantially improve cognitive outcomes in otherwise-healthy individuals and increase the probability of transient headache and sleep disruption.

Maintenance Dosing by Indication

The effective dose varies meaningfully by why the patient is using Semax:

Cognitive enhancement, focus, executive function: 200–400 mcg/day, once or twice daily, for 14–21 day cycles.

Post-viral brain fog (post-COVID, post-Lyme): 300–600 mcg/day in two divided doses for 21-day cycles. These patients often have baseline BDNF deficits and may require longer or repeated courses. I typically run 2–3 cycles spaced 3–4 weeks apart.

Neuroprotection, age-related cognitive decline: 200–300 mcg/day, once daily in the morning, with longer cycles (21 days) and structured 3-month repetition (e.g., 3 weeks on, 3 weeks off, 3 cycles per quarter).

Acute neurological support (adjunct to stroke or TBI rehabilitation): This should only occur under direct physician oversight. The Russian protocols used 300–600 mcg/day intranasally or IV/IM routes in inpatient settings; this article does not constitute a protocol for acute neurological emergencies.

NA-Semax and NA-Semax Amidate: Adjusted Dosing

Because these variants circulate primarily from research-grade suppliers rather than pharmaceutical manufacturers, concentration verification is a critical first step. Unlike the standardized Russian 0.1% pharmaceutical, research supplier concentrations vary widely: common formulations include 200 mcg/mL, 500 mcg/mL, and 1 mg/mL. Always confirm concentration with the supplier before calculating a drop-based dose.

NA-Semax Dosing Framework

Starting dose: 50–100 mcg/day, once in the morning.

Titration: Increase by 50 mcg every 3–5 days if effects are insufficient. Most patients find the effective range at 100–200 mcg/day for cognitive enhancement.

Upper limit: 300 mcg/day is a practical ceiling for most outpatient use. Some preclinical and anecdotal data suggest diminishing returns beyond this point, with increased incidence of irritability and sleep disruption.

NA-Semax Amidate Dosing Framework

Starting dose: 50 mcg/day, once in the morning.

Titration: More conservative than NA-Semax due to greater metabolic stability. Increase by 25–50 mcg per step every 5–7 days.

Effective range: 50–150 mcg/day for most cognitive and neuroprotective indications.

Key caution: The amidate form’s extended half-life means dosing in the afternoon can significantly disrupt sleep architecture. Morning-only administration is strongly preferred.

Nasal Administration Technique

The intranasal route for Semax exploits olfactory receptor neurons in the upper nasal cavity — specifically the area served by cranial nerve I — to transport the peptide directly to the CSF and brain parenchyma, bypassing the blood-brain barrier. The technique used determines how much peptide actually reaches this olfactory epithelium versus the lower nasal passages, where systemic absorption is less efficient.

Step-by-Step Protocol

1. Clear the nasal passages. Blow gently or use saline rinse 5–10 minutes before administration. Congestion from allergies or infection substantially reduces olfactory uptake and may necessitate dose deferral.

2. Tilt the head slightly forward (30–45 degrees downward). This is counterintuitive — many patients tilt back — but the olfactory epithelium is at the top of the nasal cavity, and forward tilt directs drops upward along the septum toward the olfactory cleft when sniffed gently.

3. Administer drops to one nostril at a time. With the head tilted and the dropper or spray nozzle positioned just inside the nostril, apply drops while inhaling slowly and gently through the nose. Forceful inhalation pulls the liquid to the back of the throat rather than the upper cavity.

4. Sniff gently after each set of drops — not sharply. A single slow sniff is enough to distribute the solution toward the olfactory region.

5. Remain with head forward for 1–2 minutes before switching nostrils. This allows the liquid to rest in contact with the olfactory mucosa rather than draining immediately.

6. Alternate nostrils first. Some practitioners recommend alternating which nostril receives the first dose each morning to distribute mucosal exposure evenly over time.

7. Do not eat or drink immediately before or after (15 minutes minimum). Food can stimulate drainage reflexes that clear the nasal cavity.

Spray vs. Dropper

The Russian pharmaceutical Semax comes in a spray bottle that delivers approximately 100 mcg per spray actuation (2–3 sprays per nostril = 200–300 mcg per nostril). Research-grade Semax often arrives in a sterile vial with a dropper or separate nasal spray bottle.

If using a dropper: a standard ophthalmic dropper delivers approximately 35–50 mcL per drop at normal room temperature. For the 0.1% formulation (1 mg/mL = 1,000 mcg/mL), this means:

• 1 drop ≈ 35–50 mcg
• 3 drops ≈ 100–150 mcg
• 6 drops total (3 per nostril) ≈ 200–300 mcg

These are approximations. Dropper calibration varies; verify your supplier’s stated drop volume if precision matters.

Cycling Protocols and Rest Periods

Standard Cycling

The 14–21 day on / 14–21 day off framework used for Selank and other neuropeptides applies equally to Semax. The rationale is partly pharmacological (avoiding receptor downregulation) and partly practical (aligning with the course durations used in published Russian clinical trials).

Conservative cycle: 14 days on, 14 days off. Appropriate for first-time users and those using Semax primarily as a cognitive productivity tool.

Extended cycle: 21 days on, 21 days off. Used more often in patients with documented BDNF deficiency, post-infectious brain fog, or documented cognitive decline where sustained neuroplastic signaling is the goal.

Acute course: 7–10 days on at moderate-to-high dose before a planned cognitive demand (exam period, intensive work project). Not recommended as a long-term pattern but well tolerated as an occasional approach.

Stacking with Other Peptides

Semax combines with several other peptides that are commonly used in cognitive and neuromodulation protocols:

Semax + Selank: This pairing is the most common in Russian clinical practice and among experienced integrative practitioners. Semax provides the dopaminergic drive and BDNF upregulation; Selank contributes anxiolytic and serotonergic modulation. The combination is often described as providing focused calm rather than either stimulation or sedation alone. Use standard doses of each; no dose reduction is needed when stacking these two.

Semax + BPC-157: Useful in patients where the cognitive decline is partly attributable to gut-brain axis dysfunction, chronic inflammation, or tissue repair demands. BPC-157 is administered separately (orally or subcutaneously) and there is no known pharmacokinetic interaction.

Semax + Dihexa: Both upregulate BDNF and HGF/Met signaling respectively. This is a higher-potency cognitive stack that I reserve for patients with significant cognitive impairment, not general enhancement. Doses of each should be at the lower end of the respective therapeutic range when combined.

Signs the Dose Needs Adjustment

Dose Is Too High

• Persistent headache localized to the occiput or temples (most common dose-limiting side effect)
• Sleep onset difficulty or early awakening, particularly when afternoon dosing is used
• Irritability or emotional lability out of proportion to baseline
• Pounding or pressured sensation in the head during administration

Action: Reduce by one step (50–100 mcg depending on variant) and assess for 5–7 days before reconsidering upward titration.

Dose Is Insufficient

• No perceptible shift in cognitive clarity or drive after 5–7 days at current dose
• Effects that were present in cycle one are absent in subsequent cycles (possible tolerance — consider extending washout period)

Action: Increase by one step, or extend the washout period between cycles before initiating the next course.

When to Stop

Semax has no documented physical dependence or withdrawal syndrome. Stopping at any point is safe. I advise patients to stop if they develop significant nasal mucosal irritation, persistent headache unresponsive to dose reduction, or any signs of nasal infection requiring medical treatment.

Related Articles

• Semax: The Nootropic Peptide That Amplifies BDNF and Protects the Brain — full mechanism, clinical evidence, and variant comparison
• Selank Dosage: Nasal Spray Protocol and Cycling — companion dosage guide for the anxiolytic neuropeptide most commonly stacked with Semax
• Selank vs. Semax: Which Nootropic Peptide Fits Your Cognitive Goals? — head-to-head comparison to guide choice between the two
• Nootropic Peptides: A Clinician’s Guide — broader survey of cognitive peptides and where Semax fits in the landscape
• Peptide Therapy for Women: Dosage Adjustments and Hormonal Context — how estrogen status and hormonal fluctuations affect peptide dosing

References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH 4-7 with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60.

2. Seredenin SB, Gudasheva TA. New drug design opportunities offered by semax for treatment of central nervous system disorders. Pharm Chem J. 2010;44(6):1-6.

3. Gusev EI, Skvortsova VI. Brain Ischemia. Moscow: Meditsina; 2001. (Semax clinical trial protocols for ischemic stroke, summarized in Russian neurology literature.)

4. Lebedeva IS, Panikratova YR, Sokolov OY, et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med. 2018;165(5):653-656.

5. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myronyuk IF. Semax, an ACTH 4-7 analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500.

6. Ashmarin IP, Nezavibatko VN, Levitskaya NG, Koshelev VB, Kamensky AA. Design and investigation of an ACTH 4-7 analog lacking the Pro-Gly-Pro sequence and desamino substituents. Neuropeptides. 1995;28(2):89-94.

7. Potaman VN, Antonova LV, Dubynin VA, Kamensky AA, Myasoedov NF. Entry of the synthetic neuropeptide semax into the rat blood-brain barrier via intranasal administration. Peptides. 1991;12(6):1215-1219.